The prevalence of childhood obesity has risen dramatically over the past 20 years and is associated with increased risk of pre-diabetes, type 2 diabetes, metabolic syndrome, and fatty liver disease ([@B1]). Visceral fat (adipose tissue inside the abdominal cavity) has long been hypothesized to be one of the major factors linking obesity to increased disease risks ([@B2]) and is certainly an important factor in childhood. In addition, ectopic fat deposition through the spillover of triglycerides into peripheral tissues and organs, such as muscle and liver, is also an important factor linking obesity to increased metabolic disease risk ([@B3]).

Previous studies have suggested that hepatic triglyceride accumulation varies between populations and thus may lead, in part, to different mechanisms by which metabolic abnormalities arise. For example, a large study of hepatic fat accumulation (measured by nuclear magnetic resonance spectroscopy) in 2,287 adult participants of the Dallas Heart Study ([@B4]) found that fatty liver disease was highest in Hispanics and lowest in African Americans. Interestingly, obesity, insulin resistance, or alcohol intake did not explain this striking ethnic difference. This disparity has also been reported in the pediatric population where a study of liver autopsy data from 742 children aged 2--19 years showed that 13% of all subjects had fatty liver disease (defined as ≥5% of hepatocytes with macrovesicular fat) with the prevalence increasing with age and obesity status ([@B5]). Moreover the prevalence of fatty liver (after adjusting for age and obesity) was highest in Hispanics (11.8%) and lowest in African Americans (1.5%), reflecting the trend observed in adults. These observations are supported by another recent study of adolescents by Taksali et al. ([@B6]), which did not find detectable levels of hepatic fat in obese African American compared with whites and Hispanics. Thus, fatty liver disease appears to be most problematic in Hispanics compared with other ethnic groups, and this phenomenon is evident by childhood.

A recent genome-wide association study by Romeo et al. ([@B7]) in adults identified a novel genetic factor that may provide a potential explanation for this striking ethnic difference in liver fat accumulation. A C \> G single nucleotide polymorphism (rs738409) in *PNPLA3*, which encodes an amino acid substitution (I148M), was associated with over twofold higher liver fat content in adults, with the strongest effect observed in Hispanics in whom the frequency of the G allele was much higher (48%) than in other populations (∼20%). The aim of the present study was to examine whether the effect of this PNPLA3 variant is manifested in Hispanic children and adolescents, and whether its effect was limited to an elevation in liver fat as opposed to other ectopic fat depots, insulin resistance, and/or fasting lipid levels.

RESEARCH DESIGN AND METHODS
===========================

We pooled subjects from a variety of studies that used a common protocol for assessment of body fat distribution and metabolic phenotype as described below. These subjects included 327 Hispanic children and adolescents aged 8--18 years, all of whom were genotyped, with 188 subjects having complete measures of liver and pancreatic fat fraction as well as abdominal fat distribution (visceral vs. subcutaneous) as described below. The remaining 139 subjects who were genotyped did not have liver fat measures but had extensive measures of insulin and glucose from an oral and an intravenous glucose tolerance test and fasting lipids. Data from some of these subjects has been previously reported ([@B8][@B9][@B10][@B11]--[@B12]), but this article is the first to examine the relationship between genotype and these outcomes. Participants and parents were provided with a full description of the study, and all participants signed an informed assent document while consent was obtained from their parents. All studies were approved by the University of Southern California Institutional Review Board.

Weight and height were measured to the nearest 0.1 kg and 0.1 cm, respectively, using a beam medical scale and wall-mounted stadiometer; BMI and BMI percentiles were then calculated. Total body fat was measured by dual-energy X-ray absorptiometry using a Hologic QDR 4500 W (Hologic, Bedford, MA). Abdominal fat distribution was measured by magnetic resonance imaging (MRI) on a General Electric 1.5-Tesla magnet. Slices were acquired using a 420-mm field of view (FOV) and FOV phase of 75%. Three abdominal scans were performed consecutively, and total acquisition time was 24 s per total abdominal scan. Each scan obtained 19 axial images of the abdomen with a thickness of 10 mm. After image acquisition, subcutaneous abdominal adipose tissue (SAT) and visceral adipose tissue (VAT) were segmented using image analysis software (sliceOmatic; TomoVision, Montreal, Canada) at the Image Reading Center (New York, NY). Hepatic and pancreatic fat fractions were assessed during the same MRI test using a modification of the Dixon three-point technique. Abdominal scans were acquired contiguously using a breath-hold dual-echo spoiled gradient-recalled echo sequence with repetition time of 156 ms and echo time of 2.3 ms for out-of-phase images and 4.78 ms for in-phase (IP) images acquired with flip angles of 70° and then 20° to provide T1-weighted and intermediate-weighted images, respectively. A third dual-echo gradient-echo breath-hold gradient-recalled echo sequence with two IP echoes (4.8 and 9.6 ms) was also performed to calculate spin-spin relaxation time (T2\*) ([@B13]). The fat fraction in the liver was estimated from the signal intensity index obtained from IP and out-of-phase images. Quantitative corrections for the influence of T2\* decay on the fat fraction estimates were taken into account by the third duel-echo sequence where T2\* for the liver was estimated on a pixel-by-pixel basis. Since the fat fraction was estimated from low flip-angle images (20°), the effect of T1 relaxation on the quantification was minimized. Once the fat fraction images were calculated, three consecutive slices with maximum axial coverage of the liver were selected, avoiding any major blood vessels, to report the average liver fat fraction.

In all cases, subjects were genotyped for single nucleotide polymorphism rs738409 in PNPLA3 using the TaqMan system (Applied Biosystems) ([@B14],[@B15]) with an assay available through the Applied Biosystems Assays on Demand database. Our overall genotype call rate was 97% and we obtained 100% genotype concordance of four control Centre d\'Etude du Polymorphisme Humain (CEPH) DNA samples that were included on each DNA plate. Genotype frequencies did not deviate from that expected under Hardy-Weinberg equilibrium (*P* = 0.92).

Data were analyzed using general linear models in SPSS version 16.0 with genotype as the main factor, and age, sex, and SAT volume as covariates (the overall results were similar when using no covariates in the model). Logistic regression analysis was used to examine prevalence of fatty liver by genotype. In this analysis, likely fatty liver disease was defined as a liver fat fraction \>5.5%, which is based on previous studies in adults using nuclear magnetic resonance spectroscopy ([@B16]), a technique that we have previously validated against the MRI methodology used in this study ([@B17]).

RESULTS
=======

The overall frequency of the PNPLA3 variant was 51.5%, and the allele distribution was 28% GG/47% CG/24% CC. The clinical characteristics of the subjects with liver fat measures are shown in [Table 1](#T1){ref-type="table"}. As shown in [Fig. 1](#F1){ref-type="fig"}, there was a highly significant effect of genotype on liver fat fraction with GG carriers having almost double the amount of liver fat content (*P* \< 0.0001). In post hoc analysis, there was no significant difference in liver fat fraction in CC versus CG carriers. As also shown in [Fig. 1](#F1){ref-type="fig"}, this relationship remained significant even in a younger sub-group of Hispanic children (aged 8--10 years). Since liver fat data were skewed, we repeated these analyses after log transformation, but the results were unchanged. The data also showed that overall, 38% of Hispanics had liver fat fraction \>5.5%, indicating likely nonalcoholic fatty liver disease. By comparison, 64% of GG carriers had liver fat fraction \>5.5% ([Table 2](#T2){ref-type="table"}), leading to an increased odds ratio of 4.7 for GG relative to GC/CC carriers having liver fat of \>5.5% (95% CI = 2.4--9.3; *P* \< 0.001). There was no significant effect of genotype on VAT volume, SAT volume, or pancreatic fat fraction, with or without adjustment for covariates including age, sex, and overall adiposity.

###### 

Clinical characteristics of subjects with liver fat measurements

  *n*                           188
  ----------------------------- ----------------------------------------------------
  Male/female                   59/129
  Age (years)                   13.6 ± 3.0
  BMI                           30.3 ± 8.9
  SAT volume (L)                9.2 ± 5.9
  VAT volume (L)                1.7 ± 1.1
  Liver fat fraction (%)        7.1 ± 7.2; median = 4.5; interquartile range = 5.8
  Pancreatic fat fraction (%)   5.6 ± 3.4

Values are mean ± SD except where noted.

![Liver fat fraction as a function of PNLPA3 genotype in Hispanic children and teenagers aged 8--18 years and in a subset aged 8−10 years. Data are least square means ± SE of the mean after adjusting for sex, age, and SAT; overall effect of genotype \<0.001.](zdb0121063890001){#F1}

###### 

Distribution of subjects by genotype and by liver fat fraction \>5.5%

  Genotype              Liver fat \<5.5   Liver fat \>5.5
  --------------------- ----------------- -----------------
  GG (*n* = 53)         36%               64%
  CG (*n* = 90)         67%               33%
  CC (*n* = 45)         84%               16%
  Overall (*n* = 188)   62%               38%

To determine whether rs738409 was associated with other metabolic phenotypes, we analyzed data from a different group of 139 Hispanic subjects (mean age = 10.9 ± 1.7 years; 38.1 ± 6.2% body fat) who had extensive measures of insulin and glucose outcomes from both oral and intravenous glucose tolerance tests, as well as fasting lipids, but liver fat measures were not available. There were no significant effects of genotype on any outcome related to insulin and glucose parameters or lipids, before or after adjusting for total fat, as measured by dual-energy X-ray absorptiometry, with the exception of HDL cholesterol, which was significantly lower in GG subjects by 12.7% compared with the CC and CG groups (40.9 ± 10.9 in CC vs. 37.0 ± 8.3 in CG vs. 35.7 ± 7.4 in GG; *P* = 0.03); in addition there was also a tendency toward lower free fatty acid levels in GG individuals (0.53 ± 0.21 in CC vs. 0.55 ± 0.11 in CG vs. 0.48 ± 0.1 in GG; *P* = 0.06).

DISCUSSION
==========

Since first reported in a genome-wide association study ([@B7]), *PNPLA3* has been under investigation to determine its function and mechanism of action. Importantly, association of rs738409 has been replicated in several follow-up studies with multiple liver-related phenotypes, including fat content, plasma enzyme levels, and fibrosis ([@B18][@B19][@B20]--[@B21]). For the most part, these studies have all been carried out in adult populations. However, this study now demonstrates that the effect of this *PNPLA3* variant *1*) manifests early in life in obese Hispanic children; *2*) is specific to the deposition of triglycerides in liver as opposed to other ectopic fat depots such as the pancreas and VAT or SAT; and 3) is also associated with significantly lower HDL cholesterol levels in obese Hispanics.

Recent studies have shown that *PNPLA3* is upregulated during adipocyte differentiation ([@B22]) and in response to positive energy balance, an atherogenic diet, insulin infusion, and nutritional status ([@B23],[@B24]). This suggests that *PNPLA3* could have pleiotropic metabolic effects beyond its role in hepatic triglyceride accumulation. However, prior studies have shown that the *PNPLA3* variant is not associated with major alterations in glucose homeostasis or lipoprotein metabolism ([@B7]). Based on fasting levels of insulin and glucose in adults, the G allele was not associated with insulin resistance in lean individuals but interestingly was associated with increased insulin sensitivity in obese adults. In the current study we provide evidence from both an oral and intravenous glucose tolerance test to show that there is no significantly detectable association between any fasting or post-challenge (oral and intravenous) glucose or insulin parameter in Hispanic children. These data support the idea, as previously proposed ([@B25]), that increased liver fat accumulation as a result of the G allele may be "metabolically benign," at least in terms of insulin resistance. Alternatively, the effect of rs738409 on glucose/insulin homeostasis may not manifest in children (unlike its effect on hepatic fat content) and thus take longer for it to develop. Lastly, the relatively small sample size of our study may have also precluded detecting the association of rs738409 with such metabolic phenotypes.

Another interesting finding from our study is the observation that GG carriers have significantly lower HDL cholesterol levels, which is consistent with a recent study reporting the same effect in Italian subjects ([@B21]). However, *PNPLA3* has not been uniformly associated with lipid levels in all studies. For example, associations between *PNPLA3* variation and serum lipids have either not been observed ([@B7],[@B25]) or only with apolipoprotein B-containing lipoproteins ([@B22]). Given these ambiguities, as well as those surrounding glucose/insulin measures, additional studies will be required to more fully understand the biological role of PNPLA3 in various processes related to metabolic homeostasis.

In conclusion, this study demonstrates that the rs738409 variant of *PNPLA3* influences liver fat deposition early in life in Hispanic children and adolescents. These results suggest that more effective therapeutic strategies for preventing and treating fatty liver need to be developed, especially for genetically predisposed pediatric populations.
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